Cell processing is a critical, yet often underestimated stage in advanced therapy manufacturing. Steps such as cell washing and cryopreservation introduce significant risks—including viability loss, phenotype instability, batch variability, and the introduction of cytotoxic or adventitious contaminants—whether working with CAR T, iPSC, MSC, or HSC-based clinical cell therapy products. These issues can compromise therapeutic performance or delay regulatory progress.

In this GEN webinar, our expert speaker(s) will share real-world experiences and strategies for improving product recovery and consistency during downstream processing. They will demonstrate how new tools like Optibumin 25, a chemically defined, animal-origin-free recombinant albumin, enable safe, consistent manufacturing in cell and gene therapy applications. Key takeaways from the webinar include:

• The impact of reagent selection on cell performance, final product quality, batch consistency, and risk of adventitious contaminants
• Common pain points in wash and cryopreservation protocols, including cell loss, target phenotype depletion, and DMSO toxicity
• Regulatory expectations for defined animal origin-free (AOF) reagents and the challenges of undefined human-derived components
• How Optibumin 25 improves your probability for success and enhances cell retention, viability, and post-thaw performance across multiple cell types
• Practical considerations to enhance CMC submissions

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Produced with support from: